DB05122ExperimentalSmall molecule
R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as...
- Mechanism
- Curator reviewed
R1295 is an integrin antagonist. As leukocyte integrins are key molecules in immune-mediated and inflammatory processes, R1295 may treat human inflammatory diseases such as rheumatoid arthritis.
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with R1295, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account